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This novel influenza virus A /H1N1 contains a
combination of human, swine and avian virus genes. One
of the most notable thing about this novel Influenza A/
H1N1 virus is high efficiency of human to human
transmission which has culminated into alarming spread
across the globe in very short time resulting in pandemic
(1,2). This calls for good laboratory services for rapid
diagnosis and treatment.
Influenza-like-illness (ILI) is defined as fever
(temperature of 100°F [37.8°C] or greater) and a cough
and/or a sore throat in the absence of a known cause
other than influenza.Case definition for the reporting of
pandemic (H1N1) 2009 virus infections in humans:-The
following case definition should be used to report
confirmed cases of pandemic (H1N1) 2009 virus infection
to WHO. An individual with laboratory confirmed
pandemic (H1N1) 2009 virus infection by one or more of
the following tests-Polymerase Chain Reaction (PCR);
 Viral Culture; 4-fold rise in pandemic (H1N1) 2009
virus specific neutralizing antibodies.
A probable case of novel influenza A (H1N1) virus
infection is defined as a person with an influenza-like-
illness who is positive for influenza A, but negative for
human H1 and H3 by influenza RT - PCR. A suspected
case of novel influenza A (H1N1) virus infection is defined
as a person who does not meet the confirmed or probable
case definition, and is not novel H1N1 test negative, and
is/has: a previously healthy person < 65 years hospitalized
for ILI or ILI & resides in a state without confirmed
cases, but has traveled to a state or country where there
are one or more confirmed or probable cases or ILI &
has an epidemiologic link in the past 7 days to a confirmed
case or probable case (3,4).
Testing for Novel influenza A (H1N1) Virus
Sample Collection :The duration of shedding with novel
influenza A (H1N1) virus is unknown. Therefore, until
data are available, the estimated duration of viral shedding
is based upon seasonal influenza virus infection. Infected
persons are assumed to be shedding virus and potentially
infectious from the day prior to illness onset until resolution
of fever. Infected persons should be assumed to be
contagious up to 7 days from illness onset. Some persons
who are infected might potentially shed virus and be
contagious for longer periods (e.g. young infants,
immunosuppressed, and immunocompromised persons)
(4). Diagnostic laboratory work on clinical specimens from
patients who are suspected cases of influenza A (H1N1)
swl virus infection should be conducted in BSL-2
containment conditions with the use of appropriate
personal protective equipment (PPE). All clinical specimen
manipulations should be done inside a certified biosafety
cabinet (5).
Laboratory Tests:- (6,7) A definitive diagnosis of
seasonal human influenza A or B is made by isolating the
virus or detecting it by properly validated antigen detection
or nucleic acid testing methods. A presumptive diagnosis
can be made by a validated rapid antigen or "point-of-
care" test.
1) Molecular Diagnostics:-
 Molecular diagnosis using real time reverse
transcriptase Polymerase Chain Reaction (rRT-PCR) is
currently the method of choice for diagnosis of influenza
A (H1N1) swine lineage. In India this facility is available
at National Institute of Virology (NIV), Pune and The
National Institute of Communicable Diseases (NICD),
New Delhi.The use of different target gene assays is
more appropriate for correct identification of this virus.The
following gene targets are important: type A influenza
matrix gene (M gene); haemagglutinin gene specific for
influenza A (H1N1) swl virus and haemagglutinin gene
specific for seasonal influenza A H1/H3 and other
subtypes (6,7).
The following protocols are currently available:-
 A) Influenza A -specific conventional & realtime PCR.
 B) CDC realtime RT-PCR (rRT-PCR) protocol for the
detection and   characterization of influenza A (H1N1)
(version 2009).Sequence analysis of the type A influenza
matrix gene PCR product using the primers in the WHO
protocols will differentiate between M genes of swine-
lineage and seasonal H1N1 viruses, however, additional
analysis should be performed to confirm the origin.
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2) Virus Isolation and Typing by Haemagglutination
    Inhibition or  Immunofluorescence
The traditional method of influenza virus recovery from
clinical specimens is by cell culture. Virus isolation is
usually more sensitive than the rapid culture and antigen
detection assays, it recovers novel or highly divergent
strains missed by other tests, it provides an isolate for
subsequent characterization and consideration as potential
vaccine strains, and it allows the simultaneous recovery
of other respiratory viruses if an appropriate range of
cell lines is used.Influenza virus replication within cell
culture, often using Madin Darby Canine Kidney cells
(MDCK), is detected by observing the cytopathic effect,
generally manifested by 5th day. Virus is readily isolated
(BSL-3 facilities are recommended) from the nose and
throat of humans with infection as well as blood and rectal
swabs.Virus isolation in the allantoic and amniotic cavities
of 10-11 day-old embryonated chicken eggs is labour
intensive and not commonly performed by diagnostic
laboratories. However, it yields higher viral titres, and
remains vital for vaccine production but requires biosafety
level 2 and above.Initial typing of influenza virus isolates
is most rapidly and conveniently accomplished by
immunofluorescence using commercially available type-
specific monoclonal antibodies, and should be performed
as soon as possible after isolation. The reference virus
subtyping method is the haemagglutination inhibition assay
using specific antisera, a technique that characterizes both
antigenic drift and shift. Subtyping using reverse
transcription polymerase chain reaction (RT-PCR) with
primers specific for various human and avian influenza
strains can be performed on virus isolates or directly on
clinical specimens. DNA microarrays have been used to
detect type & subtype-specific amplification sequences
(6,7).Polyclonal antibodies specific for subtype H1
seasonal influenza viruses from the WHO influenza
reagent kit will not react in the haemagglutination inhibition
(HAI) test with the current influenza A (H1N1) virus.
Results obtained using the H1 monoclonal antibodies in
the WHO kit should not be taken as conclusive and further
verification is recommended (6,7).
3) Serology
Serology can be used where specimens for virus
isolation or antigen detection are negative, inadequate, or
unavailable.Though, delayed it also provides useful,
surveillance data. Serological diagnosis of influenza is
retrospective, as it requires acute and convalescent serum
samples. Furthermore, it generally does not provide
information on the antigenic composition of circulating
strains.As influenza virus infection generally represents
reinfection, most people have some pre-existing immunity.
Thus, the detection of influenza-specific IgG or total
Specimens   Test / specimen collection Timing of 
specimen 
collection 
Respiratory 
aspirates 
(nasopharyngeal, 
tracheal) 
 
Direct detection and culture: Aspirate 
respiratory secretions into viral transport 
media (“T/M”) like  
•  Viral transport medium 
•  Hanks balanced salt solution 
•  Tryptose-phosphate broth  
•  Sucrose-phosphate broth 
•  Cell culture medium 
•  Veal infusion broth  
As soon as possible 
after onset of 
illness 
Respiratory swabs 
(nasopharyngeal, 
throat & nasal) 
 
Culture: Vigorously swab mucous membrane, especially inflamed areas, with 
swabs with synthetic tips made of polyester or Dacron and with aluminium or 
plastic shafts. Place into viral transport media (“T/M”) and break off shaft.Cotton 
tips with wooden shafts or calcium alginate swabs are not recommended.   
As soon as possible 
after onset of 
illness 
Paired sera  
 
Viral titre: Collect 5 ml of blood sample in a plain container without 
anticoagulants. 
Acute and 
convalescent 
samples 10-14 days 
apart. 
Specimen 
labeling 
Specimen container must be labeled with 2 unique patient identifiers matching the information on the 
request form. 
Specimen 
packaging 
 
Triple packaging system should be used for transport: 
-Primary container containing the specimen must be  watertight, leak-proof, and properly      
and securely capped  or screwed. 
-  Secondary leak-proof container should be used to protect  the primary container. Request form must be 
placed  outside the secondary container, using a separate plastic bag. 
- Tertiary  container (transport box) should have adequate strength for its capacity and intended use which 
can be  cleansed and disinfected. It should bear the biohazard warning label. 
     Specimens should be sent to laboratory as soon as  possible. If delay is unavoidable, keep at 4°C for up to 
72 hours. They should be kept at 4°C and upright during  transport to minimize the possibility of spillage. 
 
Table 1. Collection, Labeling, Packaging and Transport of Specimens (5)
Specimens
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antibodies on a single serum specimen is not diagnostic
of recent infection. The definitive serological diagnosis
of acute influenza requires the demonstration of increasing
antibody titres on paired acute and convalescent serum
samples.HAI (Haemagglutination Inhibition) and
microneutralization tests using influenza A (H1N1) swl
virus are expected to be able to detect antibody responses
following infection. A fourfold rise in antibody titer is taken
as positive (6,7).
4) Rapid Tests or Immunofluorescence
Immunofluorescence or enzyme immunoassay using
commercial type-specific monoclonal antibodies directed
against conserved influenza antigens are the most
common rapid assays performed directly on clinical
specimens.The availability of the neuraminidase inhibitors
has added impetus to the development of simple, rapid
antigen detection assays, sometimes called point-of-care
tests. Typically, these tests produce a visual result on an
immunochromatographic strip using influenza A or B
nucleoprotein-specific monoclonal antibodies within about
15 minutes of adding an extracted specimen. The
sensitivity and specificity of rapid-point-of-care or
immunofluorescence tests designed for direct detection
of influenza A viruses are currently unknown. It should
be emphasized that these tests will not differentiate
seasonal influenza from (H1N1) swl virus (6,7).
Interpretation of Laboratory Results (6)
A) PCR: -A sample is considered positive if results from
tests using two different PCR targets (e.g. primers
specific for universal M gene and swine H1
haemagglutinin gene) are positive but the PCR for human
H1 + H3 is negative. -If RT-PCR for multiple
haemagglutinin (HA) targets (i.e. H1, H3, and H1-swine-
lineage) give positive results in the same specimen, the
possibility of PCR contamination should first be excluded
by repeating PCR procedure using new RNA extract
from the original specimen or RNA extract from another
specimen. - If repeated positive results for multiple HA
targets are obtained, this raises the possibility of co-
infection, which should be confirmed by sequencing or
virus culture.- CDC realtime PCR assays - Results should
be interpreted as described in the CDC H1N1 real time
assay manual.(http://www.who.int/csr/resources/
publications/swineflu/realtimeptpcr/en/index.html)
- A negative PCR result does not rule out that a person
may be infected with influenza A (H1N1) virus. Results
should be interpreted in conjunction with the available
clinical and epidemiological information.- Specimens from
patients whose PCR results are negative but for whom
there is a high suspicion of A (H1N1) infection should be
further investigated and tested by other methods such as
virus culture or serology, to rule out (H1N1)infection.
B) Serology:-A 4 fold or greater rise in specific
H1N1virus antibody titres indicates recent infection.
C) Sequencing:-At this stage, sequencing of at least
one target product is essential for confirmation of
conventional PCR results.
D) Virus isolation:-Identification and typing of a cultured
influenza virus can be carried out by PCR, indirect
fluorescent antibody (IFA) testing using specific
NP(nucleoprotein) monoclonal antibodies, or HA and
antigenic analysis (subtyping) by HAI using selected
reference antisera.
E) Rapid Diagnostic Tests:-Preliminary data from the
CDC suggest that rapid influenza diagnostic tests have a
low overall sensitivity for novel influenza A (H1N1),
MMWR reports. The tests were generally more sensitive
for seasonal flu (range, 60% to 83%) than for novel
influenza A/H1N1 (8).
Referral for Confirmation and Further
Characterization:- Specimens should be forwarded to
the WHO Collaborating Centers for influenza
( WHOCCs) if  a) laboratories with no capacity for
diagnosis of influenza A viruses or virus isolation capacity
b) specimens with laboratory results indicative of influenza
A that are untypeable [ i.e. negative for influenza A (H1)
and A(H3); are not confirmed according to the WHO
criteria] (6).
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